Advocacy

AARP New Hampshire today released new state data and an infographic illustrating the impact of high prescription drug prices for Granite State residents, specifically those living with cancer, prediabetes or diabetes, and heart disease. AARP unveiled the infographic at the National Academy for State Health Policy (NASHP) annual conference as part of AARP’s nationwide Stop Rx Greed campaign to lower drug prices for all Americans.

The following is an op-ed by AARP New Hampshire State Director Todd Fahey surrounding the skyrocketing cost of prescriptions drugs.

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement after the administration announced a Notice of Proposed Rulemaking (NPRM) concerning the importation of prescription drugs:

AARP New Hampshire State Director Todd Fahey issued the following statement, applauding Senator Maggie Hassan for voting in favor of the Senate Finance Committee’s Prescription Drug Pricing Reduction Act of 2019:

On June 27, 2019, the Legislature passed HB 696, common-sense legislation to better protect New Hampshire’s older and disabled adults from abuse, neglect and exploitation. The bill, which was the product of bipartisan compromise, will soon be on its way to Governor Sununu’s desk for signature. A diverse group of stakeholders is urging the Governor to sign this important bill into law.

The home of state government is a sacred place.  In New Hampshire, we have the largest state legislative body in the country.  (424 members!)  So, we’re big but what really goes on and how does the legislative process work?

AARP New Hampshire volunteer advocate Guy Chapdelaine offered this testimony at the Senate Finance Committee hearing on May 8 in Manchester.

Doug McNutt, Associate State Director for Advocacy for AARP New Hampshire, offered this testimony at today’s Senate Finance Committee hearing.

AARP New Hampshire volunteer advocates Karen Ulmer Dorsch and Mary Roberge offered this testimony at Tuesday’s Senate Finance Committee Hearing in Concord.

The following is a statement from AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond on the approval of two bills endorsed by AARP: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (H.R. 965) and the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499).